Alcidion Delivers Record Cash Flow and Expands Healthcare Software Portfolio
Alcidion Group Limited (ASX: ALC) has reported a record fourth quarter, delivering positive operating cash flow of AU$7.7 million on customer cash receipts of AU$24.6 million, contributing to full-year positive operating cash flow of AU$6.8 million, up 19% from FY25. During the quarter, the Company secured AU$43.2 million in new contract value and renewals, including a seven-year, approximately AU$35.0 million agreement with University Hospital Sussex to deploy its Miya Precision Electronic Patient Record platform and an extension with Western Health to expand its digital healthcare solutions. Alcidion also completed the acquisition of Kyra flow products from Telstra Health, adding 31 new customers across Australia and New Zealand while strengthening its patient flow software offering. The Company finished the quarter with a cash balance of AU$20.6 million and no debt, while reaffirming FY26 guidance for revenue of approximately AU$51.6 million and EBITDA exceeding AU$5.0 million.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Alcidion Delivers Record Cash Flow and Expands Healthcare Software Portfolio
Alcidion Group Limited (ASX: ALC) has reported a record fourth quarter, delivering positive operating cash flow of AU$7.7 million on customer cash receipts of AU$24.6 million, contributing to full-year positive operating cash flow of AU$6.8 million, up 19% from FY25. During the quarter, the Company secured AU$43.2 million in new contract value and renewals, including a seven-year, approximately AU$35.0 million agreement with University Hospital Sussex to deploy its Miya Precision Electronic Patient Record platform and an extension with Western Health to expand its digital healthcare solutions. Alcidion also completed the acquisition of Kyra flow products from Telstra Health, adding 31 new customers across Australia and New Zealand while strengthening its patient flow software offering. The Company finished the quarter with a cash balance of AU$20.6 million and no debt, while reaffirming FY26 guidance for revenue of approximately AU$51.6 million and EBITDA exceeding AU$5.0 million.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au